Ziltivekimab Misses Phase 3 Cardiovascular Endpoint

Company Novo Nordisk Event Type Clinical Trial Results (Phase 3 Cardiovascular Outcomes Trial, Missed Primary Endpoint) Modality Fully human anti-IL-6 ligand monoclonal antibody Asset Ziltivekimab Target Interleukin-6 (IL-6) ligand Disease Area Established atherosclerotic cardiovascular disease with chronic kidney disease and systemic inflammation Summary Novo Nordisk…